
Renalytix AI plc RNLX
Quarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Total Current Liabilities 2011-2026 | RNLX
Annual Total Current Liabilities Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.5 M | 16.1 M | 11.8 M | 7.06 M | 3.29 M | 1.15 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.1 M | 1.15 M | 8.48 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Castle Biosciences
CSTL
|
68.7 M | $ 20.5 | 2.35 % | $ 594 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 17.26 | 5.18 % | $ 522 M | ||
|
Guardant Health
GH
|
303 M | $ 117.73 | 2.27 % | $ 14.8 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 116.4 | 1.14 % | $ 9.6 B | ||
|
Agilent Technologies
A
|
1.71 B | $ 114.6 | 0.76 % | $ 34.8 B | ||
|
Illumina
ILMN
|
1.55 B | $ 144.78 | 2.02 % | $ 23 B | ||
|
Celcuity
CELC
|
44.2 M | $ 141.5 | 0.83 % | $ 6.62 B | ||
|
Co-Diagnostics
CODX
|
3.54 M | $ 3.77 | 57.74 % | $ 5.01 M | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 21.63 | 2.25 % | $ 1.15 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.05 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 94.36 | -1.8 % | $ 6.37 B | ||
|
Interpace Biosciences
IDXG
|
5.1 M | $ 1.8 | - | $ 7.96 M | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 428.74 | 1.63 % | $ 12.4 B | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 089.93 | 0.63 % | $ 22.5 B | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Personalis
PSNL
|
39.6 M | $ 8.31 | 4.47 % | $ 742 M | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 159.19 | 1.99 % | $ 7.89 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
88.3 M | $ 9.08 | 2.02 % | $ 1.16 B | ||
|
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
36.6 M | $ 19.07 | -0.99 % | $ 427 M | ||
|
Natera
NTRA
|
310 M | $ 201.96 | -1.44 % | $ 19.9 B | ||
|
Myriad Genetics
MYGN
|
134 M | $ 3.88 | 1.71 % | $ 359 M | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 59.01 | 9.97 % | $ 3.53 B | ||
|
Senseonics Holdings
SENS
|
24.3 M | $ 6.07 | 6.3 % | $ 253 M | ||
|
QIAGEN N.V.
QGEN
|
512 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
61.4 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.74 M | $ 2.41 | 2.55 % | $ 5.54 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 255.56 | -0.68 % | $ 21.3 B | ||
|
Waters Corporation
WAT
|
1.24 B | $ 340.75 | -0.14 % | $ 20.3 B | ||
|
Thermo Fisher Scientific
TMO
|
15.2 B | $ 449.36 | -0.5 % | $ 169 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Exagen
XGN
|
14.2 M | $ 4.24 | 10.68 % | $ 91.4 M | ||
|
Neogen Corporation
NEOG
|
174 M | $ 8.85 | 0.23 % | $ 1.92 B |